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Abstract
Background: In Spanish public hospital Reproduction Units it is very problematic to perform programmed
intrauterine insemination (IUI) on weekends, if indicated. Small previous pilot studies suggest that using a GnRH
antagonist to avoid an LH weekend surge would allow to perform IUI on the following Monday, not impairing the
expected pregnancy rate.
Methods: Between 1st January 2007 and 31st December 2015, 4.782 intrauterine inseminations were performed at
Valladolid University Clinic, Spain, corresponding to 1.650 women. Of them, 911, corresponding to 695 women,
should ideally have been performed during the weekend. If it happened that a member of the Reproduction Unit
was on duty during that particular weekend, the standard protocol was not interrupted, and the IUI performed as
planned (control group, 685 IUIs). If the former was not the case, the weekend gap was bridged by administering
0.25 mg GnRH antagonist (GnRHa). Ovulation was induced by means of 250 ug recombinant HCG (rHCG) 36 h prior
to IUI on the following Monday (study group, 226 IUIs).
Results: There were no differences in the clinical pregnancy rate (13.7 cc vs. 16.2 %, p = 0.371) or in the ongoing
pregnancy rate between groups (11.9 % vs. 14.9 %, p = 0.271). The multiple pregnancy rate was also comparable in
both groups (14.7 % vs. 18.5 %, p = 0.77).
Conclusions: Women with a planned IUI which cannot be performed at the ideal date can be offered postponement
for two days with the support of GnRHa treatment, with results that are not inferior to those expected applying the
regular protocol.
Abbreviations: FSH, Follicle-stimulating hormone; GnRHa, Gonadotropin Relasing hormone antagonist;
IU, International units; IUI, Intrauterine insemination; LH, Luteinizing hormone; rHCG, recombinant Human chorionic
gonadotropin; TNMS, Total normal mobile sperm
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Background
Since their introduction into assisted reproduction treat-
ment schedules, both GnRH agonists [1] and antagonists
[2] now routinely form part, accompanied by controlled
ovarian hyperstimulation (COH), of “in vitro” fertilization
(IVF) protocols, but much less so of intrauterine insemin-
ation (IUI) protocols. Accumulation of scientific evidence
in their favor [3, 4] has led to their being recommended
for IVF by most scientific Fertility Societies [5]. The main
advantages attributed to the use of both GnRH agonists or
antagonists concomitant to COH is the suppression of an
unwanted LH peak which might lead to follicle luteiniza-
tion at the end of ovarian stimulation. The latter is associ-
ated with a significantly worse outcome of IVF cycles, or
their cancellation, if premature luteinization is suspected,
with the accompanying frustration and cost increase for
the patient [6–8]. In Reproduction Units of Spanish public
hospitals it is very problematic, for logistical reasons, to
perform IUI on weekends, if this were to be the ideal point
at which IUI should take place, i.e., 36 h after reaching
optimal follicle growth (2–3 follicles > 17 mm) and hCG
administration. In order to avoid this organizational draw-
back, Matorras et al. [9] proposed in 2006 what they called
a “weekend-free protocol” (and more appropriately should
have been called a free-weekend protocol). It consisted in
using a GnRH antagonist to avoid a very possible LH
weekend surge, according to measured follicle size and es-
tradiol levels on the previous workdays, and thus be able
to perform the IUI on the following Monday. Gonado-
tropin Releasing Hormone antagonists have the advantage
of their flexibility of use, since they can be administered at
any time of the follicular phase. They suppress LH levels,
and less so FSH levels, shortly after (6 h), so that, in the-
ory, unwanted ovulation may be delayed. The results of
the study by Matorras et al. [9] and of a similar, random-
ized one by Checa et al. [10] were extremely encouraging,
in spite of their relatively small sample size. This led us to
adopt their proposed protocol in 2007, and we are
presenting our results after 9 years of continued use in
a considerably larger patient cohort. The implementa-
tion of the protocol depended on whether a member of
the Reproduction Unit was on shift during the weekend
or not. This could not be chosen either by the patient
or the physician, because the weekend 24-h shifts are
programmed on a monthly basis, taking into account
the available personnel at the time. Thus, it is the
nearest thing to a randomized study that can be attained
in practice in a public hospital in our country, where
weekend shifts must be evenly distributed among all the
members of the Department, regardless of their particular
interests or those of their patients. The situation is entirely
different in private Reproduction Centers, where the activ-
ity is tailored to fit the needs of the attended women, so
that if an IUI has ideally to take place during a weekend
or a holiday, schedules are arranged so that it does indeed
take place.
Methods
This is a retrospective study, encompassing the experi-
ence at our center between 1st January 2007 and 31st
December 2015.
During the study period, a total 4.782 intrauterine
inseminations (IUIs) were performed at Valladolid
University Clinic, Spain, corresponding to 1.650 women.
Of them, 911 IUIs, corresponding to 695 women, should
ideally have been performed during the weekend, because
periovulatory follicles ≥ 16 mm were ultrasonographically
detected on Thursday or Friday.
If it happened that a member of the Reproduction
Unit of our Center was on duty during that particular
weekend, the standard protocol was not interrupted, and
the IUI performed as planned (control group, 685 IUIs).
If the former was not the case, the weekend gap was
bridged by administering 0.25 mg Gonadotropin Relas-
ing Hormone antagonist (GnRHa) daily in order to avoid
an unwanted LH surge and premature ovulation. Planned
ovulation was induced by means of the ambulatory ad-
ministration of 250 ug recombinant Human Chorionic
Gonadotropin (rHCG) 36 h prior to the planned IUI,
which took place on the following Monday (study group,
226 IUIs). Inclusion criteria into the IUI program of our
Center are: age less than 38, tubal permeability assessed by
means of hysterosalpingography and total normal mobile
sperm (TNMS) sperm count above 5 million/ml.
The detailed standard protocol for treatments was as
follows: Ovarian stimulation was performed by means of
50-100 IU/day recombinant Follicle-Stimulating Hormone
(rFSH) in all cases, until the desired follicular size was
attained. Ovarian stimulation was performed with any of
the two marketed recombinant FSH (rFSH) presentations
(Puregon, MSD, or Gonal-F, Merck). The standard FSH
dose was 75 IU/day, which was adjusted according to fol-
lowing criteria: patients with age <30 and/or a follicular
count >10 were treated with 50 IU/day; conversely, pa-
tients with age >35 and/or an immediately previous
monofollicular cycle were treated with 100 IU/day. The
first control was performed at day 5–7 of treatment,
and the FSH schedule adjusted if necessary. was used
indifferently. When 1–3 follicles with a diameter ≥ 17 mm
were detected, ovulation was induced by administering
250 ug recombinant HCG (Ovitrelle, Merck). When more
than 3 follicles with a diameter ≥ 17 mm or more than 5
follicles with a diameter ≥ 14 mm developed, the cycle was
aborted. In those cycles where the weekend was bridged
by administering a GnRH antagonist (Cetrorelix (Cetrotide,
Merck) or Ganirelix (Orgalutran, MSD) 0,25 mg), rFSH
treatment was maintained until the induction of ovulation
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by means of rHCG (Ovitrelle, Merck). Insemination was
performed 34–36 h later.
Semen capacitation was performed by means of the
density gradient method. Beta-HCG levels were deter-
mined 14–16 days after IUI, and if they were elevated, a
vaginal ultrasound examination was performed at 5 weeks
post-IUI, in order to ascertain embryo implantation.
The variables included into the study were: clinical and
ongoing pregnancy, total rFSH dose, number of 14–17 mm
follicles, endometrial thickness, mobile sperm count after
capacitation, and total expense on medication (taking into
account prices in Spain on 31st December 2015).
Clinical pregnancy was defined by beta-HCG elevation
plus ultrasonographic evidence of a gestational sac,
intrauterine or extrauterine, with or without detectable
cardiac activity. Ongoing pregnancy was defined by an
intrauterine normally evolving pregnancy.
Statistics
Data were processed using the Statgraphics XVII statis-
tical package (Statpoint Technologies Inc., Warrenton,
VA, U.S.A.).
For qualitative variables, we studied the frequency dis-
tribution. For continuous variables, we first calculated
their adjustment to a normal distribution by means of
the Kolmogorov-Smirnov test. The only studied variable
to follow a normal distribution was treatment cost. In
this case, the mean with a 95 % confidence interval and
standard deviation was calculated. The remaining con-
tinuous variables, which did not follow a normal distri-
bution, were compared by means of Mann–Whitney’s
test, and results expressed as means, together with the
corresponding standard deviation. Qualitative variables
were compared by means of contingency tables and the
Chi-square test. Results were considered significant if
the p-value was < 0.05.
Results
There was no difference in patient age between groups.
Owing to the protracted date of insemination, there was
a significant difference between the study and control
group in the amount of rFSH employed and the duration
of ovarian stimulation, which were both higher for the
study group (p < 0.001). The follicle count was slightly,
but significantly (p = 0.031) higher in the study group
(1.4 ± 0.9 vs. 1.2 ± 1.2). There were no differences in either
endometrial thickness or mobile sperm count between both
cohorts of patients and partners, respectively. However, the
cost of medication was significantly higher for the study
group (p < 0.001). Most importantly, there were no statisti-
cally significant differences in the clinical pregnancy rate
(13.7 % vs. 16.2 %, p = 0.371) or in the ongoing pregnancy
rate between groups (11.9 % vs. 14.9 %, p = 0.271). All the
aforementioned results are summarized in Table 1.
The multiple pregnancy rate was similar in both groups
(14.7 % vs. 18.5 %, p = 0.77), (Table 2).
Discussion
From the results of our study, it appears that bridging
the weekend gap by means of GnRHa in order to
minimize the occurrence of an LH surge and subsequent
spontaneous ovulation, and to postpone a planned IUI
until the following Monday, results in a similar pregnancy
rate. Our results are in agreement with those of two previ-
ous pilot studies [9, 10], one of them randomized, but with
a very low patient number. Both were initially reassuring,
but there always remained a fear: that a larger series might
reveal that GnRHa administration, although successful for
postponing ovulation, would not avoid premature luteini-
zation of mature follicles, and this would ultimately result
in a lower pregnancy rate. Our results, with a much larger
studied event number, and a considerable random effect
in the assignation of women to either the study or the
control group, reinforces the reassuring message provided
by the studies of Matorras et al. [9] and Checa et al. [10].
Furthermore, the only initial significant difference between
groups in our study was the periovulatory follicle count,
which was higher in the study group receiving GnRHa, a
finding that could potentially worsen the chances of suc-
cessfully bridging the weekend gap until the moment of
Table 1 Results of IUI in the study group receiving GnRHa to
bridge the weekend (n = 226), with IUI on Monday, and the
control group (n = 685), with IUI during the weekend as
scheduled
Study group Control group p-value
Age (years) 33.4 ± 2.8 33.2 ± 3.1 0.614
total rFSH per cycle (IU) 696.2 ± 295.5 596.5 ± 304.4 <0.001
Duration of stimulation (days) 10.3 ± 2.8 8.4 ± 2.8 <0.001
n follicles 14–17 mm 1.4 ± 0.9 1.2 ± 1.2 0.031
Endometrial thickness (mm) 9.0 ± 2.1 9.2 ± 3.3 0.554
Mobile sperm count (million) 14.5 ± 12.5 15.6 ± 13.3 0.230
Medication expenses (€): 452.72 ± 157.60 303.22 ± 132.93 <0.001
Clinical pregnancy (%) 31 (13.7 %) 111 (16.2 %) 0.371
Clinical pregnancy OR 0.78 (0.49–1.22)
Ongoing pregnancy (%): 27 (11.9 %) 102 (14.9 %) 0.271
Ongoing pregnancy OR 0.82 (0.53–1.26)
Table 2 Single and multiple ongoing pregnancy rate in the
study and control groups
Study group Control group
Singleton (%) 22 (81.5 %) 87 (85,3 %)
Twins (%) 4 (14.8 %) 12 (11,8 %)
Triplets (%) 1 (3.7 %) 3 (2,9 %)
Chi-square (p-value) 0.77
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IUI. In spite of it, the pregnancy rates were still compar-
able. Moreover, another potential danger associated with
the use of GnRHa, namely an increase of multiple
pregnancies, has not taken place in our study. Although
there were more multiple pregnancies in the study
group compared to controls (18.5 % vs. 14.7 %), the
difference did not reach statistical significance. In any
case, it was far lower than the one reported in the two
previous cited studies by Checa et al. (42.0 %) and
Matorras et al. (42.9 %) [9, 10]. The IUI protocol of our
Reproduction Unit mandates for cancellation of the
cycle if more than three follicles with a diameter above
16 mm or more than five with a diameter above 13 mm
are detected, and this may explain our relatively low
multiple pregnancy rate.
It might be argued, finally, that the use of additional
medication for postponing IUI until after the weekend
carries with it a considerable increase in cost, which is
true, as we have shown. However, it must be borne in
mind that this increase in cost is almost exactly half the
cost of a completely new cycle, which is offered if the
planned one is interrupted due to its unhappy coinci-
dence with a weekend. All this considered, the final
result is a net saving of expenses. Furthermore, there are
other, less quantifiable gains associated with the use of
the study protocol, such as the avoidance of the frustra-
tion for the patient associated with the interruption of a
fertilization cycle.
A final, fundamental doubt remains: would we obtain
similar results, if we were to bridge the weekend gap
without the use of any additional medication, speculating
on the survival of oocytes after an eventual spontaneous
ovulation? The answer to this question would be only
definitely provided by a randomized study, in which the
study group would be made up of women accepting not
to receive a medication which has proven successful in
previous studies, including this one. Such a scenario,
however desirable, is difficult to envisage in practice.
Until such a study can be carried out, our confirmatory
results of the previous pilot studies addressing the same
issue, this time carried out on a considerably larger
population, are reassuring.
Conclusions
Our data, together with those of the two previous pilot
studies, strongly suggest that women with a planned IUI
which cannot be performed at the ideal date for whatever
reason, can be offered postponement for two days with
the support of GnRHa treatment, with results that are not
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